C
35.70
-0.08 (-0.22%)
| Previous Close | 35.78 |
| Open | 35.21 |
| Volume | 1,323,519 |
| Avg. Volume (3M) | 2,212,036 |
| Market Cap | 3,797,552,384 |
| Price / Earnings (TTM) | 43.54 |
| Price / Earnings (Forward) | 101.01 |
| Price / Sales | 5.63 |
| Price / Book | 5.86 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 19.55% |
| Operating Margin (TTM) | 2.17% |
| Diluted EPS (TTM) | 1.15 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | -26.00% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 3.07 |
| Operating Cash Flow (TTM) | 179.44 M |
| Levered Free Cash Flow (TTM) | 160.08 M |
| Return on Assets (TTM) | 9.18% |
| Return on Equity (TTM) | 21.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bearish | Bearish |
AIStockmoo Score
1.5
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.49% |
| % Held by Institutions | 80.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Canaccord Genuity, 180.11%) | Buy |
| Median | 95.00 (166.11%) | |
| Low | 60.00 (HC Wainwright & Co., 68.07%) | Buy |
| Average | 85.00 (138.10%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 53.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Feb 2026 | 60.00 (68.07%) | Buy | 36.22 |
| 20 Feb 2026 | 67.00 (87.68%) | Buy | 34.82 | |
| Canaccord Genuity | 23 Jan 2026 | 100.00 (180.11%) | Buy | 43.98 |
| 02 Jan 2026 | 99.00 (177.31%) | Buy | 38.20 | |
| UBS | 16 Dec 2025 | 95.00 (166.11%) | Hold | 81.12 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GUYER WILLIAM | 35.97 | - | 996 | 35,826 |
| LYON JOSEPH DOUGLAS | 35.97 | 35.28 | 707 | 25,492 |
| MADUCK SEAN | 35.97 | 35.28 | 798 | 28,780 |
| MOKARI ATABAK | 35.97 | 35.28 | 698 | 25,173 |
| ROBB GARY CHARLES | 35.97 | 35.28 | 877 | 31,629 |
| WILSON JAMES N | 36.48 | 36.48 | -10,636 | -388,001 |
| Aggregate Net Quantity | -6,560 | |||
| Aggregate Net Value ($) | -241,101 | |||
| Aggregate Avg. Buy ($) | 36.06 | |||
| Aggregate Avg. Sell ($) | 35.52 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOKARI ATABAK | Officer | 03 Mar 2026 | Disposed (-) | 96 | 35.28 | 3,387 |
| ROBB GARY CHARLES | Officer | 03 Mar 2026 | Disposed (-) | 121 | 35.28 | 4,269 |
| MADUCK SEAN | Officer | 03 Mar 2026 | Disposed (-) | 110 | 35.28 | 3,881 |
| LYON JOSEPH DOUGLAS | Officer | 03 Mar 2026 | Disposed (-) | 89 | 35.28 | 3,140 |
| MOKARI ATABAK | Officer | 02 Mar 2026 | Acquired (+) | 794 | 35.97 | 28,560 |
| GUYER WILLIAM | Officer | 02 Mar 2026 | Acquired (+) | 996 | 35.97 | 35,826 |
| ROBB GARY CHARLES | Officer | 02 Mar 2026 | Acquired (+) | 998 | 35.97 | 35,898 |
| MADUCK SEAN | Officer | 02 Mar 2026 | Acquired (+) | 908 | 35.97 | 32,661 |
| LYON JOSEPH DOUGLAS | Officer | 02 Mar 2026 | Acquired (+) | 796 | 35.97 | 28,632 |
| WILSON JAMES N | Director | 24 Feb 2026 | Disposed (-) | 100,000 | 36.48 | 3,648,000 |
| WILSON JAMES N | Director | 24 Feb 2026 | Acquired (+) | 89,364 | 36.48 | 3,259,999 |
| WILSON JAMES N | Director | 24 Feb 2026 | Option execute | 100,000 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 22 Jan 2026 | Announcement | Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer |
| 31 Dec 2025 | Announcement | Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |